MINGMED
MingMed is a Chinese cancer therapy and vision care firm.
MINGMED
Industry:
Health Care Medical Product Research
Founded:
2019-10-01
Address:
Nansha, Guangdong, China
Country:
China
Website Url:
http://www.ming-med.com
Total Employee:
1+
Status:
Active
Total Funding:
110 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible LetsEncrypt Apple Mobile Web Clips Icon Nginx Euro Pound Sterling Alibaba HiChina DNS China Telecom
Similar Organizations
Healios
The UK’s leading digital healthcare company .
Impact Biomedicines
Impact Biomedicines is pioneering the development of life-changing treatments for patients.
MediPrint Ophthalmics
MediPrint Ophthalmics is a clinical stage eye care pharmaceutical company.
Navina
Navina develops an AI-driven platform that restructures patient data into intuitive patient portraits for better diagnoses and care.
Current Employees Featured
Zhang Yan Director, CEO & Founder @ MingMed
Director, CEO & Founder
Founder
Investors List
Yifeng Capital
Yifeng Capital investment in Series A - MingMed
Gaorong Capital
Gaorong Capital investment in Series A - MingMed
Oceanpine Capital
Oceanpine Capital investment in Series A - MingMed
Flower City Ventures
Flower City Ventures investment in Series A - MingMed
Yatsen Holding
Yatsen Holding investment in Series A - MingMed
JCP Capital
JCP Capital investment in Series A - MingMed
Jifeng Ventures
Jifeng Ventures investment in Series A - MingMed
Huajin Capital
Huajin Capital investment in Series A - MingMed
Hengqin Financial Investment
Hengqin Financial Investment investment in Series A - MingMed
JCP Capital
JCP Capital investment in Series A - MingMed
Official Site Inspections
http://www.ming-med.com Semrush global rank: 6.71 M Semrush visits lastest month: 851
- Host name: 120.24.242.153
- IP address: 120.24.242.153
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "MingMed"
HOME-MingMed Biotechnology Co., Ltd.
MingMed Biotechnology Co., Ltd. is a PRC-based company dedicated to the in-house discovery and development of novel drugs that address global unmet medical needs. Our R&D team is led by global top-notch scientists and …See details»
首页-因明生物医药科技股份有限公司
因明生物是一家专注于自主研发具有全球竞争力创新药物的中国企业。 拥有由多名顶级科学家、专家组成的研发团队。 产品管线包括眼科药物、重组蛋白肉毒毒素、肿瘤免疫药物及宠物免疫药物等，大部分为突破性潜在First-in-Class创新药 …See details»
MingMed - Crunchbase Company Profile & Funding
MingMed is a Chinese cancer therapy and vision care firm. MingMed is a Chinese company with global competitiveness in independent drug research and development.See details»
Our Team_MingMed Biotechnology Co., Ltd. - new.ming-med.com
Address： Building 13, Guangdong Medical Valley, Nansha District, Guangzhou E-mail： ming-med@ming-med.comSee details»
MingMed - Overview, News & Similar companies | ZoomInfo.com
Dec 1, 2021 · View MingMed (www.ming-med.com) location in Guangdong, China , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
MingMed Company Profile 2024: Valuation, Funding
Researcher and developer of pharmaceutical drugs. The company develops ophthalmic drugs, small molecule immune drugs, and cell therapies based on gene editing, providing innovative products to ophthalmology, medical beauty …See details»
Management Team_MingMed Biotechnology Co., Ltd.
Address： Building 13, Guangdong Medical Valley, Nansha District, Guangzhou E-mail： ming-med@ming-med.comSee details»
MingMed Biotechnology Co., Ltd. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for MingMed Biotechnology Co., Ltd. of Guangzhou, Guangdong. Get the latest business insights from Dun …See details»
MingMed Biotechnology Announces U.S. FDA Approval for IND …
Dec 2, 2021 · About MingMed Biotechnology (www.ming-med.com) The MingMed team is formed by top-notch global scientists and specialists, while our scientific committee consists of …See details»
关于我们_广州因明生物医药科技有限公司 - MingMed
凭借我们的研发能力及高效的营运能力，我们自主研发了一系列多元化而具有协同效应的产品管线，包括重组蛋白肉毒毒素、眼科药物、肿瘤免疫药物及宠物免疫药物，其中包括多种潜在first-in-class创新药物，且所有主要产品即将商业化。 …See details»
MingMed Biotechnology Co., Ltd. (广州因明生物医药科技股份有限 …
Sep 19, 2024 · Syngeneic mouse model that inoculated with different types of murine cancer cell lines was used to evaluate tumor growth.See details»
About Us_MingMed Biotechnology Co., Ltd.
MingMed Biotechnology Co., Ltd. is an innovative company dedicated to the in-house discovery and development of novel drugs that address global unmet medical needs. Our R&D team is …See details»
Latest Press Release on Clinical Trials News - Medindia
GUANGZHOU, China, Dec. 2, 2021 /PRNewswire/ -- MingMed Biotechnology, a clinical stage company dedicated to developing first-in-class pharmaceutical products, announced recently …See details»
MingMed Biotechnology Announces U.S. FDA Approval for IND …
GUANGZHOU, China, Dec. 2, 2021 /PRNewswire/ -- MingMed Biotechnology, a clinical stage company dedicated to developing first-in-class pharmaceutical products, announced recently …See details»
MingMed Biotechnology - Products, Competitors, Financials, …
About MingMed MingMed Biotechnology Co., Ltd. is an innovative company dedicated to the in-house discovery and development of novel drugs that address global unmet medical needs. …See details»
MingMed to Present at the 40th Annual J.P. Morgan Healthcare …
Jan 5, 2022 · MingMed Biotechnology is a clinical stage company dedicated to developing First-in-Class pharmaceutical products. Our team is formed by global top-notch scientists and …See details»
news_MingMed Biotechnology Co., Ltd.
Address： Building 13, Guangdong Medical Valley, Nansha District, Guangzhou E-mail： ming-med@ming-med.comSee details»
MingMed Biotechnology - VentureRadar
Develops novel drugs for global unmet medical needs in four therapeutic areas, focusing on ophthalmic, botulinum toxin, immuno-oncology, and pet immune therapies. "MingMed …See details»
因明生物_广州因明生物医药科技股份有限公司_亿欧数据
1 day ago · 广州因明生物医药科技股份有限公司是一家集研发、生产、销售和服务于一体的高新技术企业,专注于生物医药领域的研究与开发。 公司主要业务涵盖了药物研发、生物技术服务、 …See details»
Ophthalmic drugs_MingMed Biotechnology Co., Ltd.
We are primarily developing two ophthalmic drug product candidates QA102 and QA108, which are under clinical development for treating dry age-related macular degeneration (AMD).See details»